AGP Executive Report
Last update: 3 hours agoCancer Treatment: ImmunityBio says the first European patients have received Anktiva with BCG for certain bladder cancers, in Germany and Austria. The treatment’s EU approval also covers Liechtenstein. Health Insurance: Liechtenstein-based Squarelife underwrites Genki Native, which now offers cover from one month, with expanded preventive and dental benefits and a higher annual limit on its Premium plan. Medicines: Strong European sales of antifungal Cresemba triggered a $37.5 million milestone payment to Basilea; the medicine is approved in Liechtenstein for specified uses. Separately, the European Medicines Agency is reviewing Deanxit after reports of serious movement, memory and thinking problems, some persisting after treatment stops. Reproductive Health: Abortion remains largely illegal in Liechtenstein after Prince Alois vetoed a bill that would have allowed it during the first trimester, saying it did not adequately protect unborn life.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
